What is UCB SA?
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
0NZT · Verdict
Solid reward · low risk
0NZT scores well on cash flow and volatility with no major weaknesses flagged in the model.
Based on 75% data coverage
0NZT · Verdict
Top decile vs peers
Top decile vs peers
Current ratio 1.06
Model-based scoring. For information only — not financial advice.
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. The company is listed on the LSE in UK, with a market capitalisation of 17.30B.
The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.
For informational purposes only. Not financial advice.